NCT06665880

Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients

The Changes of Genes, Proteins, and Metabolites in Patients with Drug-resistant Epilepsy

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 16 (estimated)
• Sponsor: Xuanwu Hospital, Beijing · Academic / Other
• Sex: All
• Age: 14 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

In patients with drug-resistant epilepsy (DRE), there may be changes at the genetic, proteomic, and metabolomic levels when comparing epileptic tissues from DRE to normal tissues in traumatic brain injury (TBI). These changes could help in understanding the pathophysiological mechanisms of epilepsy and in identifying new therapeutic targets.

Detailed description

Genomical studies have identified changes in the expression of certain genes within epileptic tissues. These genes may be involved in pathways related to the balance of neuronal excitability and inhibition, synaptic transmission, and cell apoptosis. Proteomic studies will reveal changes in the abundance and modifications of proteins in epileptic tissues. These could involve proteins related to the control of neuronal excitability and synaptic transmission, such as ion channels, neurotransmitter receptors, and synaptic proteins. Metabolomic researches will reveal changes in metabolites within epileptic tissues. Epilepsy may lead to disruptions in metabolic pathways, affecting key processes such as energy metabolism, amino acid metabolism, and lipid metabolism. Sample Size: There is no minimum or maximum, but is expected to be far less than 10. In summary, patients with drug-resistant epilepsy might have changes in genes, proteomics, and metabolomics within epileptic tissues compared to normal tissue from TBI. Further research into these changes will deepen our understanding of the pathophysiology of epilepsy and guide the need for new treatment strategies.

Conditions

• Drug Resistant Epilepsy
• Traumatic Brain Injury Without Open Intracranial Wound

Interventions

Type	Name	Description
OTHER	Routine clinical treatment	Routine clinical treatment is based on the latest international guidelines for DRE.

Timeline

• Start date: 2024-11-15
• Primary completion: 2025-12-15
• Completion: 2026-12-31
• First posted: 2024-10-30
• Last updated: 2024-10-30

Locations

1 site across 1 country: China